Alclometasone Dipropionate

Summary

Alclometasone Dipropionate (CHEMBL1200989) is an approved small-molecule anti-inflammatory drug (ATC D07AB10); indicated across 3 conditions including eye disorder and skin disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: D07AB10 (+1 more)
• Indications: 3 conditions
• Clinical trials: 1
• Chemistry: 521 Da · C28H37ClO7

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1200989
Name	Alclometasone Dipropionate
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	636374
ChEBI	CHEBI:31184
ATC	D07AB10, S01BA10
Molecular formula	C28H37ClO7
Molecular weight	521
InChIKey	DJHCCTTVDRAMEH-DUUJBDRPSA-N

SMILES: CCC(=O)OCC(=O)[C@]1([C@@H](C[C@@H]2[C@@]1(C[C@@H]([C@H]3[C@H]2[C@@H](CC4=CC(=O)C=C[C@]34C)Cl)O)C)C)OC(=O)CC

IUPAC name: [2-[(7R,8S,9S,10R,11S,13S,14S,16R,17R)-7-chloro-11-hydroxy-10,13,16-trimethyl-3-oxo-17-propanoyloxy-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-17-yl]-2-oxoethyl] propanoate

ChEBI definition: A prednisolone compound having an α-chloro substituent at the 7-position, an α-methyl substituent at the 16-position and O-propanoyl groups at the 17- and 21-positions.

Pharmacological roles (ChEBI): anti-inflammatory drug.

Also known as: Aclovate, Alclometasona, Alclometasone, Alclometasone dipropionate, Modrasone, NSC-758914, SCH 22219, SCH-22219, SID56463048, ALCLOMETASONE DIPROPIONATE, SID144204277, ALCLOMETASONE-DIPROPIONATE

Patent coverage: 2,392 distinct patent families (8,201 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 5 (assay-derived). Sample: Beta-lactamase, Glucocorticoid receptor, Progesterone receptor, Cannabinoid receptor 1, Androgen receptor.

Bioactivity

ChEMBL activities: 5 potent at pChembl ≥ 5 of 6 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
NR3C1	7.85	AC50	14	nM	CHEMBL_ACT_25175980
CNR1	6.67	AC50	213.4	nM	CHEMBL_ACT_25181717
PGR	6.4	AC50	400	nM	CHEMBL_ACT_25223144
CNR1	6.24	AC50	580	nM	CHEMBL_ACT_25230838
P15207	5.03	AC50	9400	nM	CHEMBL_ACT_25232387

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
eye disorder	4	MONDO:0005328	EFO:0005752
skin disorder	4	MONDO:0005093	EFO:0000701
non-small cell lung carcinoma	2	MONDO:0005233	EFO:0003060

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01465802	PHASE2	COMPLETED	Study Of Dacomitinib (PF-00299804) In Advanced NSCLC Patients (Post Chemo Or Select First Line) To Evaluate Prophylactic Intervention On Derm And GI AEs And PRO

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).